DDW Editor Reece Armstrong speaks to Adityo Prakash, CEO of Verseon, about AI and deep learning in drug discovery and how neural networks within AI are influencing drug discovery approaches. RA: Could you explain the architectural differences between Verseon’s VersAI’s neural network and deep learning neural networks? AP: The underlying neural network for any AI […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!